Differentiation and gene expression profile of tumor-associated macrophages

Seminars in Cancer Biology

Volumn 22, Issue 4, 2012, Pages 289-297

  Schmieder, Astrid ^a   Michel, Julia ^a   Schönhaar, Kathrin ^a   Goerdt, Sergij ^a   Schledzewski, Kai ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer; Macrophage differentiation; Macrophage gene regulation; Target therapy; Tumor associated macrophages; Tumor microenvironment

Indexed keywords

ARGINASE 1; CHEMOKINE; CHEMOKINE CCL18; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DOXORUBICIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 4; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; PREDNISONE; RITUXIMAB; SORAFENIB; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

CARCINOGENESIS; CELL ACTIVATION; CELL DIFFERENTIATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; FOLLICULAR LYMPHOMA; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; HUMAN; MACROPHAGE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

ANIMALS; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROPHAGES; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84862128998     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.02.002     Document Type: Review

References (120)

1. Korkaya H., Liu S., Wicha M.S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011, 121:3804-3809.
2. Kenny P.A., Lee G.Y., Bissell M.J. Targeting the tumor microenvironment. Front Biosci 2007, 12:3468-3474.
3. Stein M., Keshav S., Harris N., Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992, 176:287-292.
4. Kzhyshkowska J., Mamidi S., Gratchev A., Kremmer E., Schmuttermaier C., Krusell L., et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006, 107:3221-3228.
5. Hogger P., Dreier J., Droste A., Buck F., Sorg C. Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998, 161:1883-1890.
6. Kodelja V., Muller C., Politz O., Hakij N., Orfanos C.E., Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998, 160:1411-1418.
7. Joerink M., Savelkoul H.F., Wiegertjes G.F. Evolutionary conservation of alternative activation of macrophages: structural and functional characterization of arginase 1 and 2 in carp (Cyprinus carpio L.). Mol Immunol 2006, 43:1116-1128.
8. Van den Bossche J., Bogaert P., van Hengel J., Guerin C.J., Berx G., Movahedi K., et al. Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood 2009, 114:4664-4674.
9. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
10. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
11. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
12. DeKoter R.P., Singh H. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science 2000, 288:1439-1441.
13. Holtschke T., Lohler J., Kanno Y., Fehr T., Giese N., Rosenbauer F., et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996, 87:307-317.
14. Krausgruber T., Blazek K., Smallie T., Alzabin S., Lockstone H., Sahgal N., et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011, 12:231-238.
15. Satoh T., Takeuchi O., Vandenbon A., Yasuda K., Tanaka Y., Kumagai Y., et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010, 11:936-944.
16. De Santa F., Narang V., Yap Z.H., Tusi B.K., Burgold T., Austenaa L., et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 2009, 28:3341-3352.
17. Hargreaves D.C., Horng T., Medzhitov R. Control of inducible gene expression by signal-dependent transcriptional elongation. Cell 2009, 138:129-145.
18. Lee J.H., Skalnik D.G. CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J Biol Chem 2005, 280:41725-41731.
19. Ramirez-Carrozzi V.R., Braas D., Bhatt D.M., Cheng C.S., Hong C., Doty K.R., et al. A unifying model for the selective regulation of inducible transcription by CpG islands and nucleosome remodeling. Cell. 2009, 138:114-128.
20. Lawrence T., Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 2011, 11:750-761.
21. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
22. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signalling. Nature 1996, 380:627-630.
23. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6:137-143.
24. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
25. Gorgoni B., Maritano D., Marthyn P., Righi M., Poli V. C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. J Immunol 2002, 168:4055-4062.
26. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009, 15:425-430.
27. Zhang B., Yao G., Zhang Y., Gao J., Yang B., Rao Z. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011, 66:1879-1886.
28. Porrata L.F., Ristow K., Colgan J., Habermann T., Witzig T., Thompson C., et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin lymphoma. Haematologica 2012, 97:262-269.
29. Zaki M.A., Wada N., Ikeda J., Shibayama H., Hashimoto K., Yamagami T., et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch. 2011, 459:361-366.
30. Fujiwara T., Fukushi J., Yamamoto S., Matsumoto Y., Setsu N., Oda Y., et al. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol 2011, 179:1157-1170.
31. Komohara Y., Hasita H., Ohnishi K., Fujiwara Y., Suzu S., Eto M., et al. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci 2011, 102:1424-1431.
32. Lin J.Y., Li X.Y., Tadashi N., Dong P. Clinical significance of tumor-associated macrophage infiltration in supraglottic laryngeal carcinoma. Chin J Cancer 2011, 30:280-286.
33. Ma Y.Y., He X.J., Wang H.J., Xia Y.J., Wang S.L., Ye Z.Y., et al. Interaction of coagulation factors and tumor-associated macrophages mediates migration and invasion of gastric cancer. Cancer Sci 2011, 102:336-342.
34. Mantovani A., Allavena P., Sozzani S., Vecchi A., Locati M., Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004, 14:155-160.
35. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
36. Borrello M.G., Alberti L., Fischer A., Degl'innocenti D., Ferrario C., Gariboldi M., et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 2005, 102:14825-14830.
37. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
38. Shchors K., Shchors E., Rostker F., Lawlor E.R., Brown-Swigart L., Evan G.I. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 2006, 20:2527-2538.
39. Staller P., Sulitkova J., Lisztwan J., Moch H., Oakeley E.J., Krek W. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 2003, 425:307-311.
40. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
41. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98:295-303.
42. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
43. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006, 66:11432-11440.
44. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-310.
45. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12:715-723.
46. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
47. Liu M., Sakamaki T., Casimiro M.C., Willmarth N.E., Quong A.A., Ju X., et al. The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 2009, 70:10464-10473.
48. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
49. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007, 178:6867-6875.
50. Pang B., Zhou X., Yu H., Dong M., Taghizadeh K., Wishnok J.S., et al. Lipid peroxidation dominates the chemistry of DNA adduct formation in a mouse model of inflammation. Carcinogenesis 2007, 28:1807-1813.
51. Meira L.B., Bugni J.M., Green S.L., Lee C.W., Pang B., Borenshtein D., et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008, 118:2516-2525.
52. Cobbs C.S., Whisenhunt T.R., Wesemann D.R., Harkins L.E., Van Meir E.G., Samanta M. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res 2003, 63:8670-8673.
53. Hmadcha A., Bedoya F.J., Sobrino F., Pintado E. Methylation-dependent gene silencing induced by interleukin 1beta via nitric oxide production. J Exp Med 1999, 190:1595-1604.
54. Kulbe H., Thompson R., Wilson J.L., Robinson S., Hagemann T., Fatah R., et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592.
55. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
56. Oguma K., Oshima H., Aoki M., Uchio R., Naka K., Nakamura S., et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J 2008, 27:1671-1681.
57. Nickoloff B.J., Ben-Neriah Y., Pikarsky E. Inflammation and cancer: is the link as simple as we think. J Invest Dermatol 2005, 124:x-xiv.
58. Wang B., Li Q., Qin L., Zhao S., Wang J., Chen X. Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol 2011, 12:43.
59. Nakanishi Y., Nakatsuji M., Seno H., Ishizu S., Akitake-Kawano R., Kanda K., et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011, 32:1333-1339.
60. Harris R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17:55-67.
61. Hagemann T., Wilson J., Kulbe H., Li N.F., Leinster D.A., Charles K., et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175:1197-1205.
62. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007, 7:1271-1285.
63. Banerjee S., Halder K., Bose A., Bhattacharya P., Gupta G., Karmahapatra S., et al. TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages. Carcinogenesis 2011, 32:1789-1797.
64. Rius J., Guma M., Schachtrup C., Akassoglou K., Zinkernagel A.S., Nizet V., et al. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008, 453:807-811.
65. Werno C., Menrad H., Weigert A., Dehne N., Goerdt S., Schledzewski K., et al. Knockout of HIF-1alpha in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis 2010, 31:1863-1872.
66. White J.R., Harris R.A., Lee S.R., Craigon M.H., Binley K., Price T., et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 2004, 83:1-8.
67. Pello O.M., De Pizzol M., Mirolo M., Soucek L., Zammataro L., Amabile A., et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood 2012, 119:411-421.
68. Wang Y.C., He F., Feng F., Liu X.W., Dong G.Y., Qin H.Y., et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res 2010, 70:4840-4849.
69. Kopan R., Ilagan M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233.
70. Sanchez-Martin L., Estecha A., Samaniego R., Sanchez-Ramon S., Vega M.A., Sanchez-Mateos P. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 2011, 117:88-97.
71. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
72. Biswas S.K., Gangi L., Paul S., Schioppa T., Saccani A., Sironi M., et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006, 107:2112-2122.
73. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
74. Allavena P., Germano G., Marchesi F., Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011, 317:664-673.
75. Wong S.C., Puaux A.L., Chittezhath M., Shalova I., Kajiji T.S., Wang X., et al. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 2010, 40:2296-2307.
76. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
77. Rodriguez P.C., Quiceno D.G., Zabaleta J., Ortiz B., Zea A.H., Piazuelo M.B., et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004, 64:5839-5849.
78. Gray M.J., Poljakovic M., Kepka-Lenhart D., Morris S.M. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene 2005, 353:98-106.
79. Sharda D.R., Yu S., Ray M., Squadrito M.L., De Palma M., Wynn T.A., et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J Immunol 2011, 187:2181-2192.
80. Pucci F., Venneri M.A., Biziato D., Nonis A., Moi D., Sica A., et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood resident monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
81. De Palma M., Murdoch C., Venneri M.A., Naldini L., Lewis C.E. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007, 28:519-524.
82. Mason S.D., Joyce J.A. Proteolytic networks in cancer. Trends Cell Biol 2011, 21:228-237.
83. Gocheva V., Wang H.W., Gadea B.B., Shree T., Hunter K.E., Garfall A.L., et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010, 24:241-255.
84. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9:259-270.
85. Hagemann T., Wilson J., Burke F., Kulbe H., Li N.F., Pluddemann A., et al. Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol 2006, 176:5023-5032.
86. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 2004, 64:7022-7029.
87. Gratchev A., Guillot P., Hakiy N., Politz O., Orfanos C.E., Schledzewski K., et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol 2001, 53:386-392.
88. Schmieder A., Schledzewski K., Michel J., Tuckermann J.P., Tome L., Sticht C., et al. Synergistic activation by p38MAPK and glucocorticoid signaling mediates induction of M2-like tumor-associated macrophages expressing the novel CD20 homolog MS4A8A. Int J Cancer 2011, 129:122-132.
89. Martinez F.O., Gordon S., Locati M., Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
90. Solinas G., Schiarea S., Liguori M., Fabbri M., Pesce S., Zammataro L., et al. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 2010, 185:642-652.
91. Wang F.Q., So J., Reierstad S., Fishman D.A. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer 2006, 118:879-888.
92. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-205.
93. Allavena P., Chieppa M., Bianchi G., Solinas G., Fabbri M., Laskarin G., et al. Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin Dev Immunol 2010, 5471:79.
94. Politz O., Gratchev A., McCourt P.A., Schledzewski K., Guillot P., Johansson S., et al. Stabilin-1 and -2 constitute a novel family of fasciclin-like hyaluronan receptor homologues. Biochem J 2002, 362:155-164.
95. Schledzewski K., Falkowski M., Moldenhauer G., Metharom P., Kzhyshkowska J., Ganss R., et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 2006, 209:67-77.
96. Kzhyshkowska J., Workman G., Cardo-Vila M., Arap W., Pasqualini R., Gratchev A., et al. Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol 2006, 176:5825-5832.
97. Rivera L.B., Bradshaw A.D., Brekken R.A. The regulatory function of SPARC in vascular biology. Cell Mol Life Sci 2011, 68:3165-3173.
98. Clark C.J., Sage E.H. A prototypic matricellular protein in the tumor microenvironment - where there's SPARC, there's fire. J Cell Biochem 2008, 104:721-732.
99. Prevo R., Banerji S., Ferguson D.J., Clasper S., Jackson D.G. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001, 276:19420-19430.
100. Mouta Carreira C., Nasser S.M., di Tomaso E., Padera T.P., Boucher Y., Tomarev S.I., et al. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001, 61:8079-8084.
101. Chen H., Campbell R.A., Chang Y., Li M., Wang C.S., Li J., et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009, 113:1992-2002.
102. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21.
103. Vaish V., Sanyal S.N. Chemopreventive effects of NSAIDs on cytokines and transcription factors during the early stages of colorectal cancer. Pharmacol Rep 2011, 63:1210-1221.
104. Greten F.R., Arkan M.C., Bollrath J., Hsu L.C., Goode J., Miething C., et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007, 130:918-931.
105. Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011, 70 Suppl. 1:i104-i108.
106. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
107. Lin L., Amin R., Gallicano G.I., Glasgow E., Jogunoori W., Jessup J.M., et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009, 28:961-972.
108. Robinson S.C., Scott K.A., Wilson J.L., Thompson R.G., Proudfoot A.E., Balkwill F.R. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003, 63:8360-8365.
109. Loberg R.D., Ying C., Craig M., Day L.L., Sargent E., Neeley C., et al. Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 2007, 67:9417-9424.
110. Vergunst C.E., Gerlag D.M., Lopatinskaya L., Klareskog L., Smith M.D., van den Bosch F., et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008, 58:1931-1939.
111. Valleala H., Hanemaaijer R., Mandelin J., Salminen A., Teronen O., Monkkonen J., et al. Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 2003, 73:2413-2420.
112. Rogers T.L., Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011, 9:177.
113. Coscia M., Quaglino E., Iezzi M., Curcio C., Pantaleoni F., Riganti C., et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14:2803-2815.
114. Huang Z, Zhang Z, Jiang Y, Zhang D, Chen J, Dong L, et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release 2012; [Epub ahead of print].
115. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
116. Edwards J.P., Emens L.A. The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE in murine macrophages. Int Immunopharmacol 2010, 10:1220-1228.
117. Chi K.H., Wang Y.S., Kao S.J. Improving radioresponse through modification of the tumor immunological microenvironment. Cancer Biother Radiopharm 2012, 27:6-11.
118. Crawford Y., Ferrara N. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 2009, 30:624-630.
119. Farinha P., Masoudi H., Skinnider B.F., Shumansky K., Spinelli J.J., Gill K., et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169-2174.
120. Canioni D., Salles G., Mounier N., Brousse N., Keuppens M., Morchhauser F., et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008, 26:440-446.